Skip to content
Explore the latest in technology trends, digital transforma…

Zimbabwe Rejects ‘Unbalanced’ American Healthcare Assistance Package Because of Data Apprehensions

Medical funding illustration
The offered American funding was aimed at programmes for HIV/Aids treatment and prevention, tuberculosis, and malaria.

Zimbabwe has turned down a major American health deal worth 367 million US dollars (272 million pounds) over five years because of the United States' demand for sensitive biological samples.

The decision came to light following a government memo from December was disclosed, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".

An official representative has since clarified that the US was requesting biological samples for scientific study and commercial gain but was unwilling to guarantee the resulting advantages from future treatments.

"We must now begin the difficult and regrettable task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.

The US Embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.

A doctors' association in Zimbabwe has called for more negotiations to find a agreement agreeable to both sides so the country's critical HIV programme can be sustained.

Broader Implications

Zimbabwe's decision comes after a similar case in Kenya, where a high court suspended a related deal with the US following legal challenges were filed about the safety of Kenyans' health data.

After resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).

The agency had overseen aid for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.

Based on reports, 16 African countries have so far signed these new health pacts, constituting over $18.3bn in committed funds.

Details of the Rejected Agreement

The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".

"We believe this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via US-supported initiatives," the Ambassador commented.

However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".

"Zimbabwe was being asked to surrender its biological resources and data indefinitely, without any corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.

"In essence, our nation would provide the raw materials for medical research without any certainty that the end products would be available to our people if a future disease outbreak emerge."

Sovereignty and International Frameworks

Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining systems previously established via the global organization.

Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.

"This system is intended to ensure that when a country contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."

These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.

"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation might be arranged in a manner that honours the sovereignty and interests of each country."

Medical Community Response

Medical experts stated it acknowledged the government's concerns, but urged that talks need to persist considering a large portion of the nation's HIV programmes depended on international support.

"Where technical issues arise, including those involving data governance or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group said.

The situation underscores the ongoing tensions between receiving much-needed international aid and protecting national sovereignty in an increasingly data-driven world.

About the author

Adam Hunter

A tech journalist and digital strategist with over a decade of experience covering emerging technologies and their impact on business and society.

Chronicle Digital

Type to search articles.